Efficacy of nano curcumin in F2-isoprostanes in male rats treated with Cisplatin and Methotrexate as chemotherapy drugs

Soheir N. Abd El-Rahman, Agriculture Research Center, Egypt
Suhailah, S. Al-Jameel, University of Dammam, Saudi Arabia

Purpose: This work is based on nanoparticipation technique for preparation of curcumin nanoparticles (CURNPs) and study the effect of CURNPs (60, 30 mg/kg b.w) as antioxidants on the nephrotoxicity induced by cisplatin (CDDP) (6 mg/kg b.w i.p) and methotrexate (MTX) (20 mg/kg b.w i.p).
Design/methodology/approach: Physicochemical characterization of CURNPs was studied by Zetasizer Nano ZS, TEM and BET surface area. Urea, creatinine, SOD, CAT and F2-Isoprostanes (F2-isoPs) in serum were estimated. Also, morphological changes of kidney were studied.
Findings: The results indicated that the CDDP and MTX induced increase of urea, creatinine and F2-IsoPs concentrations and decline of serum antioxidant enzymes (SOD and CAT) activities. On the other hand, urea, creatinine and F2-IsoPs, were reduced and (SOD and CAT) activities were increased significantly (p<0.05) in the CURNPs (60, 30 mg/kg b.w) + CDDP/ MTX treated groups. Moreover, CURNPs (60, 30 mg/kg b.w) + CDDP/ MTX treated groups resulted in a marked of morphological protection against the drugs induced nephrotoxicity and confirmed the pathological improvement in the kidney tissue.
Originality/value: This study concluded that CURNPs has a strong potential to be used as a strong antioxidant in CDDP and MTX nephrotoxicity. Most importantly, CURNPs (60 mg/kg b.w) was much more effective and better nephroprotective agent than CURNPs (30 mg/kg b.w). These findings provide further understanding for the possible therapeutic effects of CURNPs in further pre-clinical and clinical research.
Keywords: Curcumin nanoparticles (CURNPs), F2-isoprostans (F2-isoPs), Cisplatin (CDDP), Methotrexate (MTX), Nephrotoxicity.

IJSR_VNABD EL-RAHMAN_AL-JAMEEL-Itemid=.pdf
IJSR_VNABD EL-RAHMAN_AL-JAMEEL-Itemid=.pdf
It's only fair to share...Tweet about this on TwitterShare on FacebookShare on LinkedInShare on Google+Email this to someonePrint this page

Be the first to comment

Leave a Reply

Your email address will not be published.


*